RxDoctor Payments Data

Vibhav Bansal, MD

Vascular Neurology · Evansville, INNPI 1730337569

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $6,500 of the $8,984 with a category attached, or 72.4%. Abbott accounts for 86.2% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2020 at $6,671 and has fallen 84.8% since, to $1,015 in 2025.

$8,984in general payments, 2019–2025

Across 57 payments — averaging $157.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$8K
  • Medtronic$649
  • Johnson & Johnson$237
  • Microvention, Inc.$75
  • Scientia Vascular$54
  • Stryker$35
  • plus $193 from 8 others
$371,781in research payments, 2019–2025

Across 49 payments — averaging $7587.37 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • E.r. Squibb & Sons, L.L.C.$222K
  • Janssen Research & Development, LLC$124K
  • Medical Device Business Services, Inc.$26K

What the payments were for

  • Consulting fees$6,50072%
  • Speaking & faculty fees$1,00011%
  • Food & beverage$1,48417%

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few vascular neurology providers in Indianato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$163,993
Medicare patients
246
Services billed
657

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban16$16,238
BrilintaTicagrelor25$15,239
ClopidogrelClopidogrel Bisulfate84$652
Venlafaxine Hcl ErVenlafaxine Hcl21$206
Atorvastatin Calcium23$155
Amlodipine Besylate12$38

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$27$16,23816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few vascular neurology providers in Indianaon file to place this against a meaningful peer group, so we don't.

Other vascular neurology in Evansville

Where these figures come from

Is this you, or does something look wrong? →